Core Viewpoint - Weitai Medical-B (2235.HK) has received approval from the National Medical Products Administration for its core product, the Equil insulin pump, expanding its use to children and adolescents aged 3-17 years, thus providing new treatment options for millions of diabetic patients in China [1] Group 1: Product Approval and Market Expansion - The Equil insulin pump was previously approved only for adult diabetes patients, and the recent approval allows it to be used for a younger demographic [1] - This expansion in indications demonstrates the company's strong independent R&D capabilities in the field of diabetes monitoring, treatment, and management [1] - The approval is expected to strengthen the company's leading position in the industry and strategically expand the market space for its products [1] Group 2: Future Focus and Innovation - The company plans to continue focusing on the global development of diabetes monitoring, treatment, and management methods [1] - There will be ongoing efforts to drive technological and product innovation in related fields [1]

Core Viewpoint - MicroTech Medical-B (02235) has seen a stock increase of over 4%, currently trading at 8.06 HKD, following the approval of its core product, the Equil patch insulin pump, for use in children and adolescents aged 3-17 years with diabetes, expanding its market reach significantly [1][1][1] Group 1: Product Approval and Market Expansion - The National Medical Products Administration (NMPA) has approved the Equil patch insulin pump for pediatric use, which previously was only available for adult diabetes patients [1][1] - This approval provides a new treatment option for millions of children and adolescents with diabetes in China [1][1] Group 2: Clinical Trials and Efficacy - The clinical trials for this indication were led by the Children's Hospital affiliated with Zhejiang University School of Medicine, in collaboration with six top children's hospitals across the country [1][1] - The trials demonstrated the effectiveness and safety of Continuous Subcutaneous Insulin Infusion (CSII) in treating diabetes in children and adolescents [1][1] Group 3: Product Advantages - The patch insulin pump offers several advantages over traditional tube-based insulin pumps, including more precise and safe insulin delivery, ease of use, cost-effectiveness, enhanced privacy, and elimination of issues such as tube blockage and tangling [1][1][1]

Core Viewpoint - MicroTech Medical-B (02235) has seen a stock increase of over 4% following the approval of its core product, the Equil patch insulin pump, for use in children and adolescents aged 3-17, expanding its market reach significantly [1] Group 1: Product Approval and Market Expansion - The National Medical Products Administration (NMPA) has approved the Equil patch insulin pump for pediatric use, which previously was only available for adult diabetes patients [1] - This approval provides a new treatment option for millions of children and adolescents with diabetes in China [1] Group 2: Clinical Trials and Efficacy - The clinical trials for this indication were led by the Children's Hospital affiliated with Zhejiang University School of Medicine, in collaboration with six top children's hospitals across the country [1] - The trials demonstrated the effectiveness and safety of Continuous Subcutaneous Insulin Infusion (CSII) in treating diabetes in children and adolescents [1] Group 3: Product Advantages - The patch insulin pump offers several advantages over traditional tube-based insulin pumps, including more precise and safe insulin delivery, greater convenience and flexibility in use, cost-effectiveness, enhanced privacy, and the absence of issues like tube blockage and tangling [1]

Group 1 - The core product, Equil patch insulin pump, has received approval from the National Medical Products Administration for use in children and adolescents aged 3-17, expanding its market from adult diabetes patients to millions of domestic children and adolescents with diabetes [1][2] - The clinical trial for this indication was led by Zhejiang University School of Medicine Children's Hospital, in collaboration with six top children's hospitals in the country, demonstrating the effectiveness and safety of Continuous Subcutaneous Insulin Infusion (CSII) in treating diabetes in children and adolescents [1] - The patch insulin pump offers advantages over traditional tubing insulin pumps, including more precise and safe insulin delivery, convenience in wearing, cost-effectiveness, enhanced privacy, and elimination of issues like clogging and tubing entanglement [1] Group 2 - The expansion of the indication reflects the company's strong independent R&D capabilities in the field of diabetes monitoring, treatment, and management, further solidifying its leading position in the industry and strategically expanding the market space for its products [2] - The company will continue to focus on the global development of diabetes monitoring, treatment, and management methods, driving innovation in related technologies and products [2]

Core Viewpoint - The approval of the Equil patch insulin pump for children and adolescents expands its application from adult diabetes patients to a new demographic, providing millions of young diabetes patients in China with a new treatment option [1][2] Group 1: Product Approval and Market Expansion - The Equil patch insulin pump has received approval from the National Medical Products Administration, allowing its use for children and adolescents aged 3-17 years [1] - This approval is expected to significantly enhance the market potential for the product, addressing the needs of millions of domestic children and adolescents with diabetes [1][2] Group 2: Clinical Trials and Efficacy - The clinical trials for this indication were led by the Children's Hospital affiliated with Zhejiang University School of Medicine, in collaboration with six top children's hospitals across the country [1] - The trials demonstrated the effectiveness and safety of Continuous Subcutaneous Insulin Infusion (CSII) in treating diabetes in children and adolescents [1] Group 3: Product Advantages - The patch insulin pump offers several advantages over traditional tube-based insulin pumps, including more precise and safe insulin delivery, ease of use, cost-effectiveness, enhanced privacy, and the absence of issues like clogging and tubing entanglement [1] Group 4: Company Strategy and Future Focus - The expansion of the indication reflects the company's strong independent R&D capabilities in the field of diabetes monitoring, treatment, and management [2] - The company aims to solidify its leading position in the industry and will continue to focus on global developments in diabetes monitoring, treatment, and management, driving innovation in related technologies and products [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 MicroTech Medical (Hangzhou) Co., Ltd. 微 泰 醫 療 器 械（ 杭 州 ）股 份 有 限 公 司 （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股份代號： 2235） 自願性公告 本公司貼敷式胰島素泵兒童及 青少年適應症獲批 本公告乃微泰醫療器械（杭州）股份有限公司（「本公司」及其附屬公司，「本集 團」）自願發佈，目的是讓其股東（「股東」）及潛在投資者了解本集團的最新發展。 本公司董事（「董事」）會（「董事會」）欣然宣佈，我們的核心產品（「核心產品」） 之一Equil貼敷式胰島素泵兒童及青少年適應症，近日已獲國家藥品監督管理局 （「國家藥監局」）批准。此次獲批使該產品的適用範圍在原有「成人糖尿病患者」 基礎上，進一步擴展至3-17周歲兒童及青少年群體，為數百萬國內兒童及青少 年糖尿病患者提供了全新治療選擇。 該適應症擴展的臨 ...

Group 1 - CD Capital GP Ltd reduced its stake in MicroTech Medical (02235) by 93,200 shares at an average price of HKD 8.61 per share, totaling approximately HKD 802,500 [1] - After the reduction, CD Capital GP Ltd holds approximately 8.3968 million shares, representing a holding percentage of 4.96% [1]

Group 1 - CD Capital GP Ltd reduced its stake in MicroTech Medical (02235) by 93,200 shares at an average price of HKD 8.61 per share, totaling approximately HKD 802,500 [1] - After the reduction, CD Capital GP Ltd holds approximately 8.3968 million shares, representing a 4.96% ownership stake [1] - The transaction involves other related parties including CD Capital Healthcare FUND V, L.P., CDBI GP, Ltd., and several CDBI Partners funds [1]

Group 1 - CD Capital GP Ltd reduced its stake in MicroTech Medical-B (02235) by 93,200 shares at an average price of HKD 8.61 per share, totaling approximately HKD 802,500 [1] - After the reduction, CD Capital GP Ltd holds approximately 8.3968 million shares, representing a 4.96% ownership stake [1] - The transaction involves other related parties including CD Capital Healthcare FUND V, L.P., CDBI GP, Ltd., and several CDBI Partners funds [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 微泰醫療器械（杭州）股份有限公司 (於中華人民共和國注冊成立) 呈交日期: 2025年9月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02235 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 169,235,842 | RMB | | 1 RMB | | 169,235,842 | | 增加 / 減少 (-) | | | | | | RMB | | | | 本月底結存 | | | 169,235,842 | RMB | | 1 RMB | | 169,235,842 | | 2. 股份分類 | 普通股 | ...